Talk:Ovarian cancer
Revision as of 18:12, 6 April 2018 by Jwarner (talk | contribs) (Created page with "The purpose of this page is to record, in reverse chronological order, conversations about content changes for the accompanying main page. ==April 2018== *User:Jwarner: R...")
The purpose of this page is to record, in reverse chronological order, conversations about content changes for the accompanying main page.
April 2018
- User:Jwarner: Rucaparib is now FDA approved "for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy." However, ARIEL3 specified that patients had received at least two previous platinum-based chemotherapy regimens, so we will leave the regimen in the current setting (maintenance after second-line chemotherapy for platinum-sensitive disease).